Please login to the form below

Not currently logged in
Email:
Password:

alteplase

This page shows the latest alteplase news and features for those working in and with pharma, biotech and healthcare.

Biogen hands out $120m upfront for Remedy stroke drug

Biogen hands out $120m upfront for Remedy stroke drug

The US biotech major is paying $120m upfront for rights to the drug, which is vying to be the first new treatment for ischaemic stroke since alteplase - still the only approved

Latest news

  • AZ's Brilinta disappoints in stroke trial AZ's Brilinta disappoints in stroke trial

    Currently the only drug approved for the treatment of ischemic stroke is Genentech's tissue plasminogen activator (tPA) Activase (alteplase), although this remains a controversial therapy as the drug has an

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    as Genentech/Boehringer Ingelheim's Activase/Actilyse (alteplase), but Translational Sciences believes there is significant room for improvement.

  • Lundbeck's desmoteplase flunks phase III stroke trial Lundbeck's desmoteplase flunks phase III stroke trial

    An older thrombolytic called alteplase (tPA) - sold by Genentech as Activase - is already approved to treat stroke, but remains a controversial therapy as the drug has an extremely narrow therapeutic window ... The drug is also easier to administer than

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics